HC Wainwright & Co. Reiterates Buy on ADC Therapeutics, Maintains $8 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on ADC Therapeutics (NYSE:ADCT) and maintained a price target of $8.
August 08, 2024 | 11:29 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on ADC Therapeutics and maintained a price target of $8.
The reiteration of a Buy rating and the maintenance of a price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100